Pulmonary Safety of Repeat Doses of Staccato Loxapine for Inhalation in Healthy Volunteers.

Trial Profile

Pulmonary Safety of Repeat Doses of Staccato Loxapine for Inhalation in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2009

At a glance

  • Drugs Loxapine (Primary)
  • Indications Migraine; Schizophrenia
  • Focus Adverse reactions
  • Sponsors Alexza Pharmaceuticals
  • Most Recent Events

    • 06 May 2009 Actual end date added as 1 Apr 2009.
    • 06 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top